Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma

Olthof, Pim B.; Franssen, Stijn; Keulen, Anne-Marleen van; Geest, Lydia G. van der; Hoogwater, Frederik J.H.; Coenraad, Minneke J.; Driel, Lydi M.J.W. van; Erdmann, Joris I.; Mohammad, Nadia Haj; Heij, Lara; Klümpen, Heinz‐Josef; Tjwa, Eric T.; Iersel, Liselot Valkenburg-van; Verheij, Joanne; Koerkamp, Bas Groot

doi:10.1016/j.hpb.2023.06.019

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intrahepatic CCA management leans toward liver resection for solitary tumors, with LT considered for tumors ≤ 3 cm or when associated with cirrhosis. [25] Colorectal liver metastasis LT for colorectal liver metastasis continues to gain traction. A single-center cohort of 13 patients with colorectal liver metastasis demonstrated promising disease-free survival (~79% at 2 y) in high-selective patients with Oslo scores of 0-1 (O-062).…”

Section: Cholangiocarcinomamentioning

confidence: 99%

Proceedings of the 28th Annual Congress of the International Liver Transplantation Society

Shaji Mathew,

Shingina,

Khan

et al. 2024

Liver Transplantation

View full text Add to dashboard Cite

The 2023 Joint International Congress of the International Liver Transplantation Society (ILTS), the European Liver and Intestine Transplant Association (ELITA), and the Liver Intensive Care Group of Europe (LICAGE) held in Rotterdam, Netherlands, marked a significant recovery milestone for the liver transplant community post-COVID-19. With 1159 participants and a surge in abstract submissions, the event focused on “Liver Disorders and Transplantation: Innovations and Evolving Indications.” This conference report provides a comprehensive overview of the key themes discussed during the event, encompassing Hepatology, Anesthesia & Critical Care, Acute Liver Failure, Infectious Disease, Immunosuppression, Pediatric Liver Transplantation, Living Donor Liver Transplantation, Transplant Oncology, Surgical Approaches, and Machine Perfusion. The congress provided a platform for extensive discussions on a wide range of topics, reflecting the continuous advancements and collaborative efforts within the liver transplant community.

show abstract

Section: Cholangiocarcinomamentioning

confidence: 99%

Proceedings of the 28th Annual Congress of the International Liver Transplantation Society

Shaji Mathew,

Shingina,

Khan

et al. 2024

Liver Transplantation

View full text Add to dashboard Cite

show abstract

“…Moreover, it could reduce the morbidity of surgery and improve overall survival. Up to 30% of those treated may have Subclinical metastatic disease that was not visible on beforehand crosssectional staging imaging 18 . Therefore, laparoscopy is the best option for diagnosing ICC initially and providing effective treatment.…”

Section: Diagnostic Laparoscopymentioning

confidence: 99%

Advances in The Treatment of Intrahepatic Cholangiocarcinoma-ICLCA

Jha,

Vinayak B Angadi,

Kuriri

et al. 2023

Int J Tre Onc Sci

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (iCLCA) is a fatal hepatobiliary tumor becoming more common. For a long time, it was largely ignored as an uncommon cancer and commonly misdiagnosed as carcinoma of unidentified origin; nonetheless, significant clinical and research attention has been dedicated to it lately. First-line (gemcitabine and cisplatin), second-line (FOLFOX), and adjuvant (capecitabine) systemic chemotherapy is the accepted standard of treatment. iCLCA is genetically unique from hepatocellular carcinoma, with multiple targetable genetic abnormalities reported to be far. Indeed, FGFR2, NTRK fusions, IDH1, and BRAF targetable mutations have been thoroughly studied, and clinical evidence on pharmacologically targeting these oncogenic drivers is emerging. In addition, the role of immunotherapy has been investigated and is a hot topic. There is a need for therapeutic interventions for these ailments. Our review focuses on Intrahepatic cholangiocarcinoma, cholangiocarcinoma, Extrahepaticcholangiocarcinoma, Vascular Epidermal Growth Factor, IDH inhibitors, and Liver Cancer.

show abstract

“…This was demonstrated to be feasible in several countries within Euracan centres. 41 , 42 , 43 Development of specific HRQoL for rare cancer is ongoing in the EORTC, an associate partner of EURACAN. 44 …”

Section: Introductionmentioning

confidence: 99%

Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

Blay,

Casali,

Ray-Coquard

et al. 2024

The Lancet Regional Health - Europe

Self Cite

View full text Add to dashboard Cite

Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma

Cited by 4 publications

References 39 publications

Proceedings of the 28th Annual Congress of the International Liver Transplantation Society

Proceedings of the 28th Annual Congress of the International Liver Transplantation Society

Advances in The Treatment of Intrahepatic Cholangiocarcinoma-ICLCA

Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

Contact Info

Product

Resources

About